Initiator Pharma A/S (STO:INIT)

Market Cap	202.62M -45.3%
Revenue (ttm)	n/a
Net Income	-19.83M
EPS	-0.32
Shares Out	68.45M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,889
Average Volume	56,543
Open	3.090
Previous Close	2.990
Day's Range	2.990 - 3.090
52-Week Range	2.560 - 6.950
Beta	0.10
RSI	50.01
Earnings Date	Feb 20, 2026

About Initiator Pharma

Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor, which completed phase IIb clinical trial primarily targeting the dopamine system for treatment resistant organic erectile dysfunction, as well as completed phase I to treat neuropathic pain; and IP2018, a monoamine reuptake inhibitor which completed Phase IIa for the treatment of psychogenic erectile dysfunction. The ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2016
• Employees: 1
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: INIT

Financial Performance

Financial numbers in DKK